Search

Boehringer Ingelheim opens Health Management Centre in China

Boehringer Ingelheim opens Health Management Centre in China The new Health Management Centre integrates animal disease and health diagnostics as well as monitoring tools The centre further strengthens the company’s ability to provide services along the f

Launch of Frontline flagship store on Tmall

Boehringer Ingelheim launches Frontline flagship store on Tmall to sell selling full range of pet parasiticides.

garbage game

Learn more about marine pollution and find out how long it takes for garbage to dissolve in the oceans.

U.S. FDA approves first treatment for generalized pustular psoriasis flares in adults

Boehringer Ingelheim announces the U.S. FDA has approved the first treatment for generalized pustular psoriasis (GPP) flares in adults

GPP Interview with Professor Barker

An interview with Prof. Barker about generalized pustular psoriasis, its burden on patients and how patient outcomes can be improved

CHMP_opinion_Nintedanib_SSc-ILD

Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease

Rare Diseases: Rare but not alone

We are committed to listen and learn from patients with rare diseases to deliver breakthrough therapies.

Health Equity: No distance is too far

India is hosting the G20 summit. The leading theme of the G20 summit emphasizes health equity and sustainability as part of the agenda. How we provide access to healthcare for rural areas in India.

Flood-disaster-in-Germany-donation-from-Boehringer-Ingelheim

Boehringer Ingelheim increases donation for emergency flood relief to EUR 1 million

World Patient Safety Day 2021

As a sign of support for World Patient Safety Day, Boehringer Ingelheim lights up buildings in orange.

EMPRISE-Study

ArisGlobal acquires Boehringer Ingelheim technology

Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal

Mental health: a $1 trillion burden demanding policy action

Nearly one billion people around the world live with a mental health condition, yet an estimated 70% don’t have access to the help they need.

Boehringer Ingelheim invests in precision cancer treatments

Boehringer Ingelheim Venture Fund invests in Synthetica as part of its commitment to advancing innovative, next-generation cancer therapies

FDA Grants Breakthrough Status to Schizophrenia Treatment

Boehringer Ingelheim and Click Therapeutics receive FDA Breakthrough Device Designation for schizophrenia prescription digital therapeutic

The power of patient advocacy in cancer care

Larry, a retired US Navy veteran, and Jeff, UICC President, have more in common than a cancer diagnosis: they share a passion for patient empowerment.

Winners of BVDzero Scholarship Programme

Boehringer Ingelheim announces winners of BVDzero Scholarship Programme

New vaccine against Bovine Respiratory Disease

Boehringer Ingelheim’s Bovalto Respi Intranasal is a new respiratory vaccine for active immunization of cattle against Bovine Respiratory Disease.

New production center for Veterinary Public Health

Boehringer Ingelheim invests more than €200 million to establish a strategic production center for Veterinary Public Health in Lyon, France.

Official partner to Cat Care for Life

Boehringer Ingelheim announces its new partnership with the CatCareforLife program.

GastroGard the first imported equine drug in China

GastroGard® approved as the first imported equine drug in China. Boehringer Ingelheim officially starts equine health business in China.

Approval for Aservo EquiHaler equine asthma therapy

Boehringer Ingelheim receives approval for Aservo® EquiHaler®, industry first equine asthma therapy

Zongertinib positive results non-small cell lung cancer

Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients

preserved-heart-failure-treatment-FDA-US-approval

US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction

empulse-trial-benefit-acute-heart-failure

Empagliflozin provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE Phase III trial

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers